NCT06965361View on ClinicalTrials.gov

Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Triple Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

CompletedOBSERVATIONAL
Enrollment

54

Participants

Timeline

Start Date

January 2, 2021

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

carboplatin

carboplatin use due to its effectiveness in increasing pathological complete remission (pCR) rates and improving survival outcomes

DEVICE

carboplatin

used in the treatment of triple-negative breast cancer (TNBC) due to its effectiveness in achieving pathological complete response (pCR) and breast-conserving surgery (BCS) rates.

Trial Locations (1)

75270

Shamim, Karachi

All Listed Sponsors
collaborator

Jinnah Sindh Medical University

OTHER

lead

Ziauddin University

OTHER

NCT06965361 - Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Triple Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy | Biotech Hunter | Biotech Hunter